XML 33 R32.htm IDEA: XBRL DOCUMENT v2.4.1.9
Collaboration and License Agreements (Details) (USD $)
 3 Months Ended 1 Months Ended 52 Months Ended 1 Months Ended 45 Months Ended 0 Months Ended 1 Months Ended
Mar. 31, 2015
Mar. 31, 2014
Sep. 30, 2007
Sep. 30, 2009
Dec. 31, 2012
Oct. 31, 2012
May 31, 2009
Apr. 30, 2009
Dec. 31, 2012
Nov. 13, 2009
Nov. 30, 2010
Nov. 30, 2009
Dec. 31, 2014
Collaboration and License Agreements                          
Total collaborative arrangements revenue $ 28,932,000us-gaap_Revenues $ 14,605,000us-gaap_Revenues                      
Net amounts receivable from third party 862,000us-gaap_AccountsReceivableNetCurrent                       10,000us-gaap_AccountsReceivableNetCurrent
Collaborative arrangement                          
Collaboration and License Agreements                          
Total collaborative arrangements revenue 2,300,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= us-gaap_CollaborativeArrangementMember		                        
Actavis Plc                          
Collaboration and License Agreements                          
Total collaborative arrangements revenue 25,325,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		 8,447,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                      
Up-front fee received     70,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                    
Equity investment in the entity's capital stock 25,000,000us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
Asset value for contingent equity investment by collaborative party recorded at inception of agreement     9,000,000irwd_ContingentEquityInvestmentAssetValue
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                    
Incremental deferred revenue related to contingent equity investment     9,000,000us-gaap_DeferredRevenueAdditions
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                    
Net cost sharing offset or incremental expense related to research and development expense 3,200,000irwd_NetCostSharingOffsetRelatedToResearchAndDevelopmentExpenseReimbursement
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		 600,000irwd_NetCostSharingOffsetRelatedToResearchAndDevelopmentExpenseReimbursement
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                      
Net amounts receivable from third party 4,300,000us-gaap_AccountsReceivableNetCurrent
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
Collaborative arrangements revenue 25,137,000irwd_CollaborativeArrangementProfitShareSettlementAmountRecognized
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		 [1],[2] 8,447,000irwd_CollaborativeArrangementProfitShareSettlementAmountRecognized
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		 [1],[2]                      
Selling, general and administrative costs incurred by the Company (7,688,000)us-gaap_SellingAndMarketingExpense
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		 [1] (7,999,000)us-gaap_SellingAndMarketingExpense
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		 [1]                      
The Company's share of net profit (loss) 17,449,000irwd_CollaborativeArrangementNetIncomeLossRecognized
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		 448,000irwd_CollaborativeArrangementNetIncomeLossRecognized
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                      
Actavis Plc | Convertible preferred stock (Note 11)                          
Collaboration and License Agreements                          
Issuance of Convertible preferred stock (in shares)       2,083,333us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_StatementClassOfStockAxis
= us-gaap_ConvertiblePreferredStockMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                  
Actavis Plc | Development and sales milestones                          
Collaboration and License Agreements                          
Cumulative license fees and development milestone payments received 205,000,000irwd_LicenseFeesAndMilestonePaymentReceivedCumulative
/ irwd_AchievementOfMilestoneAxis
= irwd_DevelopmentAndSalesMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
Actavis Plc | Development milestones                          
Collaboration and License Agreements                          
Number of milestones achieved under collaboration agreement 6irwd_NumberOfMilestonesAchieved
/ irwd_AchievementOfMilestoneAxis
= irwd_DevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
Milestone payment received         135,000,000irwd_MilestonePaymentReceived
/ irwd_AchievementOfMilestoneAxis
= irwd_DevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                
Actavis Plc | Commercialization milestone                          
Collaboration and License Agreements                          
Percentage of net profit from commercialization 50.00%irwd_CollaborativeArrangementPercentageOfNetProfit
/ irwd_AchievementOfMilestoneAxis
= irwd_CommercializationMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
Percentage of net loss from commercialization 50.00%irwd_CollaborativeArrangementPercentageOfNetLoss
/ irwd_AchievementOfMilestoneAxis
= irwd_CommercializationMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
Actavis Plc | Maximum | Sales milestones                          
Collaboration and License Agreements                          
Milestone Payment to be Received by Company upon Milestone Achievement First Commercial Drug Launch 100,000,000irwd_MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievementFirstCommercialDrugLaunch
/ irwd_AchievementOfMilestoneAxis
= irwd_SalesMilestonesMember
/ us-gaap_RangeAxis
= us-gaap_MaximumMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
AstraZeneca                          
Collaboration and License Agreements                          
Total collaborative arrangements revenue 1,230,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_AstraZenecaMember		 408,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_AstraZenecaMember		                      
Up-front fee received           25,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ us-gaap_TypeOfArrangementAxis
= irwd_AstraZenecaMember		              
Net cost sharing offset or incremental expense related to research and development expense 300,000irwd_NetCostSharingOffsetRelatedToResearchAndDevelopmentExpenseReimbursement
/ us-gaap_TypeOfArrangementAxis
= irwd_AstraZenecaMember		 400,000irwd_NetCostSharingOffsetRelatedToResearchAndDevelopmentExpenseReimbursement
/ us-gaap_TypeOfArrangementAxis
= irwd_AstraZenecaMember		                      
AstraZeneca | Commercialization milestone                          
Collaboration and License Agreements                          
Percentage of net profit from commercialization           55.00%irwd_CollaborativeArrangementPercentageOfNetProfit
/ irwd_AchievementOfMilestoneAxis
= irwd_CommercializationMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_AstraZenecaMember		              
Percentage of net loss from commercialization           55.00%irwd_CollaborativeArrangementPercentageOfNetLoss
/ irwd_AchievementOfMilestoneAxis
= irwd_CommercializationMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_AstraZenecaMember		              
Almirall, S.A.                          
Collaboration and License Agreements                          
Total collaborative arrangements revenue 101,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		 4,481,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		                      
Up-front fee received             40,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		   6,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		        
Milestone Payment to be Received by Company upon Milestone Achievement First Commercial Drug Launch 4,000,000irwd_MilestonePaymentToBeReceivedByCompanyUponMilestoneAchievementFirstCommercialDrugLaunch
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		                        
Asset value for contingent equity investment by collaborative party recorded at inception of agreement               6,000,000irwd_ContingentEquityInvestmentAssetValue
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		          
Incremental deferred revenue related to contingent equity investment               6,000,000us-gaap_DeferredRevenueAdditions
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		          
Almirall, S.A. | Convertible preferred stock (Note 11)                          
Collaboration and License Agreements                          
Equity investment in the entity's capital stock                   15,000,000us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
/ us-gaap_StatementClassOfStockAxis
= us-gaap_ConvertiblePreferredStockMember
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		      
Issuance of Convertible preferred stock (in shares)                   681,819us-gaap_StockIssuedDuringPeriodSharesNewIssues
/ us-gaap_StatementClassOfStockAxis
= us-gaap_ConvertiblePreferredStockMember
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		      
Almirall, S.A. | Development milestones                          
Collaboration and License Agreements                          
Milestone payment received                     20,000,000irwd_MilestonePaymentReceived
/ irwd_AchievementOfMilestoneAxis
= irwd_DevelopmentMilestonesMember
/ us-gaap_TypeOfArrangementAxis
= irwd_AlmirallSAMember		    
Astellas Pharma Inc.                          
Collaboration and License Agreements                          
Total collaborative arrangements revenue 2,276,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_AstellasPharmaIncMember		 1,269,000us-gaap_Revenues
/ us-gaap_TypeOfArrangementAxis
= irwd_AstellasPharmaIncMember		                      
Net profit share adjustment 1,200,000irwd_CollaborativeArrangementAdjustmentToShareOfNetProfit
/ us-gaap_TypeOfArrangementAxis
= irwd_AstellasPharmaIncMember		                        
Up-front fee received                       30,000,000us-gaap_ProceedsFromLicenseFeesReceived
/ us-gaap_TypeOfArrangementAxis
= irwd_AstellasPharmaIncMember		  
Canada and Mexico | Actavis Plc                          
Collaboration and License Agreements                          
Royalty revenue $ 200,000irwd_CollaborativeArrangementRevenueRecognizedInRoyaltyPayments
/ us-gaap_StatementGeographicalAxis
= irwd_CanadaAndMexicoMember
/ us-gaap_TypeOfArrangementAxis
= irwd_ActavisPlcMember		                        
[1] Includes only collaborative arrangement revenue or selling, general and administrative costs attributable to the cost-sharing arrangement with Actavis.
[2] Includes a net profit share adjustment of approximately $1.2 million recorded during the quarter ended March 31, 2015, as described above.